Literature DB >> 25681527

Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics.

Behzad Etemad1, Melissa Ghulam-Smith1, Oscar Gonzalez1, Laura F White2, Manish Sagar3.   

Abstract

Recent studies suggest that single genome amplification (SGA) as compared to standard bulk PCR and virus stocks from 293T transfection versus short term passage in peripheral blood mononuclear cells (PBMC) yield a less biased representation of HIV-1 envelope characteristics. In 9 different subjects, genetic diversity, divergence, and population structure were not significantly different among SGA or bulk PCR amplified envelope V1-V3 segments. In these subjects, 293T transfection derived virus stocks with SGA or bulk PCR amplified envelopes have similar infectivity, replication kinetics, co-receptor usage, and neutralization susceptibility. While PBMC passage as compared to the 293T derived virus stocks had similar co-receptor usage, PBMC viruses were less neutralization susceptible to some specific antibodies. Our results suggest that the method of envelope sequence amplification, either SGA or bulk PCR, does not have a significant impact on the genotypic and phenotypic properties of the virus envelope quasispecies.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diversity; Envelope; HIV-1; Neutralization; Replication; Single genome amplification

Mesh：

Substances：

Year:  2015        PMID： 25681527      PMCID： PMC4394631          DOI： 10.1016/j.jviromet.2015.01.006

Source DB:  PubMed          Journal:  J Virol Methods        ISSN： 0166-0934            Impact factor:   2.014


  36 in total

1.  Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.

Authors:  Nikolaos Chatziandreou; Ana Belen Arauz; Ines Freitas; Phyu Hninn Nyein; Gregory Fenton; Shruti H Mehta; Gregory D Kirk; Manish Sagar
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

2.  Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.

Authors:  A Björndal; H Deng; M Jansson; J R Fiore; C Colognesi; A Karlsson; J Albert; G Scarlatti; D R Littman; E M Fenyö
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.

Authors:  Manish Sagar; Hisashi Akiyama; Behzad Etemad; Nora Ramirez; Ines Freitas; Suryaram Gummuluru
Journal:  J Infect Dis       Date:  2012-03-06       Impact factor: 5.226

4.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count.

Authors:  D Vlahov; N Graham; D Hoover; C Flynn; J G Bartlett; J B Margolick; C M Lyles; K E Nelson; D Smith; S Holmberg; H Farzadegan
Journal:  JAMA       Date:  1998-01-07       Impact factor: 56.272

6.  Envelope diversity, characteristics of V3 region and predicted co-receptor usage of human immunodeficiency viruses infecting north Indians.

Authors:  Raiees Andrabi; Rajesh Kumar; Manju Bala; Ambili Nair; Prakash Ss; Vandana Kushwaha; Kalpana Luthra
Journal:  J Microbiol       Date:  2012-11-04       Impact factor: 3.422

7.  Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C.

Authors:  Nina H Lin; Carlos Becerril; Francoise Giguel; Vladimir Novitsky; Sikhulile Moyo; Joseph Makhema; Myron Essex; Shahin Lockman; Daniel R Kuritzkes; Manish Sagar
Journal:  Virology       Date:  2012-09-03       Impact factor: 3.616

8.  HIV-1 persistence in CD4+ T cells with stem cell-like properties.

Authors:  Maria J Buzon; Hong Sun; Chun Li; Amy Shaw; Katherine Seiss; Zhengyu Ouyang; Enrique Martin-Gayo; Jin Leng; Timothy J Henrich; Jonathan Z Li; Florencia Pereyra; Ryan Zurakowski; Bruce D Walker; Eric S Rosenberg; Xu G Yu; Mathias Lichterfeld
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

9.  HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners.

Authors:  Victor Pena-Cruz; Behzad Etemad; Nikolaos Chatziandreou; Phyu Hninn Nyein; Shannon Stock; Steven J Reynolds; Oliver Laeyendecker; Ronald H Gray; David Serwadda; Sandra J Lee; Thomas C Quinn; Manish Sagar
Journal:  Retrovirology       Date:  2013-12-26       Impact factor: 4.602

10.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.

Authors:  Jinghe Huang; Gilad Ofek; Leo Laub; Mark K Louder; Nicole A Doria-Rose; Nancy S Longo; Hiromi Imamichi; Robert T Bailer; Bimal Chakrabarti; Shailendra K Sharma; S Munir Alam; Tao Wang; Yongping Yang; Baoshan Zhang; Stephen A Migueles; Richard Wyatt; Barton F Haynes; Peter D Kwong; John R Mascola; Mark Connors
Journal:  Nature       Date:  2012-09-18       Impact factor: 49.962
View more
  8 in total

1.  High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.

Authors:  Rebecca Nedellec; Joshua T Herbeck; Peter W Hunt; Steven G Deeks; James I Mullins; Elizabeth D Anton; Jacqueline D Reeves; Donald E Mosier
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-12       Impact factor: 2.205

2.  Single Genome Sequencing of Expressed and Proviral HIV-1 Envelope Glycoprotein 120 (gp120) and nef Genes.

Authors:  David J Nolan; Susanna L Lamers; Rebecca Rose; James J Dollar; Marco Salemi; Michael S McGrath
Journal:  Bio Protoc       Date:  2017-06-20

3.  HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility.

Authors:  Ludy Registre; Yvetane Moreau; Sila Toksoz Ataca; Surya Pulukuri; Timothy J Henrich; Nina Lin; Manish Sagar
Journal:  J Virol       Date:  2020-01-06       Impact factor: 6.549

4.  Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity.

Authors:  Melissa Ghulam-Smith; Alex Olson; Laura F White; Charles S Chasela; Sascha R Ellington; Athena P Kourtis; Denise J Jamieson; Gerald Tegha; Charles M van der Horst; Manish Sagar
Journal:  mBio       Date:  2017-10-24       Impact factor: 7.867

5.  Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates.

Authors:  Julio C C Lorenzi; Pilar Mendoza; Yehuda Z Cohen; Lilian Nogueira; Christy Lavine; Joseph Sapiente; Marie Wiatr; Nelly R Mugo; Andrew Mujugira; Sinead Delany; Jairam Lingappa; Connie Celum; Michael S Seaman; Marina Caskey; Michel C Nussenzweig
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

6.  Pre-existing infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity.

Authors:  Allison S Thomas; Yvetane Moreau; Wenqing Jiang; John E Isaac; Alexander Ewing; Laura F White; Athena P Kourtis; Manish Sagar
Journal:  Cell Rep Med       Date:  2021-10-19

7.  Molecular linkage tracing of HIV-1 transmission events in seroconcordant couples in Guangxi Province, Southeastern China.

Authors:  Nidan Wang; Zhenzhu Tang; Yijia Li; Peiyan Xie; Yiming Shao
Journal:  Springerplus       Date:  2016-11-25

8.  Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.

Authors:  Nina Lin; Oscar A Gonzalez; Ludy Registre; Carlos Becerril; Behzad Etemad; Hong Lu; Xueling Wu; Shahin Lockman; Myron Essex; Sikhulile Moyo; Daniel R Kuritzkes; Manish Sagar
Journal:  EBioMedicine       Date:  2016-05-05       Impact factor: 8.143
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.